Neurology Pain Management Board Certified Expert Witness

Expert Witness No.1897

Education

1982-1986                 University of Pittsburgh
Pittsburgh, PA
M.D.

1978-1982                 Dartmouth College
Hanover, NH
A.B.; Cum Laude; with distinction in major subject

Training

Clinical Fellow

Department of Neurology (Pain Management)
Johns Hopkins University
Baltimore, MD

1987-1990                 Neurology Resident
Chief Resident
Dartmouth-Hitchcock Medical Center
Hanover, NH

1986-1987                 Intern (Internal Medicine)
Allegheny General Hospital
Pittsburgh, PA

1999-2000                 Interventional Pain Management Training Florida Pain Clinic
                                    Ocala, FL

Employment

1998-Present            Private Practice at a Headache and Pain Center in Florida

1996-1998                 Palm Beach Neurological Group, Palm Beach Gardens and Jupiter FL

1990-1996                 Neurological Consultants, Inc., Beverly, MA

1983-1984                 Tutoring of first-year medical students

1981-1982                 Research Assistant, University of California (San Francisco)
Department of Neurology-study of pain

1980                           Laboratory Assistant and Phlebotomist, New England Deaconess Hospital, Boston, MA

Positions Held

2000-2002                 Columbia Hospital West Palm Beach-Pain Management

1996-Present            Consulting Staff -Jupiter Medical Center and Palm Beach Gardens
                                    Medical Center FL

1999-2000                 Consulting Staff- Ocala Regional Hospital, Ocala, FL

1996-1999                 Consulting Staff -Savannas Hospital, Port St. Lucie, FL

1990-1996                 Active Staff Beverly Hospital, Beverly MA
Consulting Staff Addison Gilbert Hospital, Gloucester, MA

1995-1996                 Chairman, Subsection of Neurology, Beverly Hospital

1993-1995                 Chairman, Institutional Review Board, Beverly Hospital

1989-1990                 Instructor in Clinical Medicine, Dartmouth Medical School

Board Certification

11/1991                      Neurology - American Board of Psychiatry and Neurology

11/2000                      Pain Management – ABPN

National Board of Medical Examiners

2/28/98                       American Society of Neuroimaging MRI/CT Certification

State Medical Licenses

Florida
Massachusetts (previous)

Professional Societies:

American Pain Society
American Academy of Neurology
American Association for the Study of Headache
American Association of Electrodiagnostic Medicine
National Headache Foundation
American Society of Neuroimaging
American Council for Headache Education
Florida Society of Neurology
Southern Pain Society

Subspecialty Interests:

Headache and Pain evaluation and treatment
Peripheral Nerve Disorders
Electromyography and nerve conduction studies
Neuroimaging
Traumatic Neurological Injuries

Professional References

Available upon Request

Publications

Available upon Request

Clinical Research Studies

1996
Alnitidan-protocol ALN-INT-16, for the Acute Treatment of Migraine.  Janssen Phase III.

Cerestat-Protocol 534.11 for the Treatment of Patients with Ischemic Stroke.  Boehringer Ingelheim Phase III.

Lubeluzole-Protocol LUB-INT-13, for the Treatment of Patients with Ischemic Stroke.  Janssen Phase III.

Tacrine-Protocol 970-68-22, Treatment of Patients with Dementia of the Alzheimer’s type. Parke Davis.

Milameline-Protocol 979-15 for the Treatment of Patients with Probable Alzheimer’s Disease. Parke Davis

Metrifonate-Protocol X-95-018 in Patients with Probable Alzheimer’s Disease; extension to Protocol D95-018.  Parke Davis.

Metrifonate-Protocol U96-001, Long Term Treatment with Metrifonate for Patients with Probable Alzheimer’s Disease.  Park Davis.

UCB L059-Protocol RPCE94AI403 Add on Treatment in Epileptic patients with partial onset seizures. UCB S.A., Phanna sector, Phase III.

Maximum-Protocol 136-043, in the Treatment of acute Migraines, headache pain.  Zeneca Pharmaceuticals, Phase III.

MK-462 Protocol 022-00, in the Treatment of  Acute Migraine Pain, extension portion. Merke, Phase III.

Rizatriptan-Protocol 046-00, in the Treatment of Migraine Pain.  Merke.  Phase III.

UCB-L059-Protocol RPCE-94,T-1403, Follow up study on Treatment in Epileptic Patient with Partial onset seizures, UCB-SA, Pharma Sector. Phase III.

1997
L-754-030-Protocol 101-00,in the Treatment of Postherpetic Neuralgia.  Merke, Phase IIA.

Rizatriptan/Rapidisc-Protocol 049-00,in the Treatment of Acute Migraine pain. Merke, Phase III.

Gabapentin-Protocol 945-213, in Treatment of Newly diagnosed with Partial Epilepsy. Parke Davis Phase III.

Alniditan S.C.-Protocol ALN-USA-18, in the Treatment of Acute Migraine Attacks. Janssen, Phase III.

Alniditan S.C.-Protocol ALN-17, in the Acute Treatment of Migraine. Janssen Phase III.

LU25-09-Protocol 9G208, in the Treatment of Alzheimer’sDisease. H.Lundbeck A/S, Phase III.

Lazabenmide-Protocol PDL-IOOOP, in the Treatment of Alzheimer’s Disease. Protodigm,Phase III.

Naratriptan-Protocol S2WA4002, for the Treatment of    Migraine in subjects who do not respond to Oral Sumatriptan.  Glaxo Wellcome, Phase III.

Clomethiazole-Protocol SA-CMZ-0009, in the Treatment of Patients with Acute Ischemic Stroke. Astra, Phase II.

Clomethiazole-Protocol SA-CMA-0010, in the Treatment of Patients with Acute Intracerebral Hemorrhage. Astra, Phase II.

Clomethiazole-Protocol SA-CMZ-0011, in the Treatment of Patients treated with t-PA for acute Ischemic Stroke.Astra Phase II.

Metrifonate-Protocol D97-019 in the Treatment of Alzheimer’s Disease. Bayer, Phase III.

Zydis Selegiline-Protocol Z/SEL/97/025, as in Adjunct in the Management of Parkinsonian patients being treated with Levodopa, M.D.S. Harry, Phase III.

Sertraline-Protocol R-0552, in elderly patients with major Depression.  Pfizer, Phase IV.

1998
4991W93-Protocol CIAA2001, in the Acute Treatment of
Migraine Headache. Glaxo Wellcome Phase II.

Pregabalin-Protocol 1008-014-026, for Treatment of painful Diabetic Peripheral Neuropathy.  Parke Davis Phase II/III.

Idebenone-Protocol PNFP-004, for the Treatment of probable Alzheimer’s Disease. Takeda America Phase III.

Idebenone-added to Treatment with Donepezil-Protocol PNFP-007, for Patient with probable Alzheimer’s Disease, Takeda America Phase III.

Pregabalin-Protocol 1008-015-026 for the Treatment of Painful Diabetic Neuropathy Parke Davis Phase II/III.